Actively Recruiting
Phase 1 Study of BMS-986506 Alone or with Other Drugs for Advanced Clear Cell Renal Cell Carcinoma
Led by Bristol-Myers Squibb · Updated on 2026-08-11
281
Participants Needed
11
Research Sites
47 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying BMS-986506 in people with advanced Clear Cell Renal Cell Carcinoma ccRCC, a type of kidney cancer. This first-in-human phase 11b trial aims to determine if BMS-986506 is safe and can be tolerated when given alone or combined with other treatments. The study focuses on participants with advanced or metastatic ccRCC who have had prior therapies or are newly treated depending on the trial part. Participants receive BMS-986506 alone or in combination with Pumitamig andor Ipilimumab at specified doses on scheduled days. The trial includes multiple parts dose escalation and expansion phases for monotherapy and combination therapies. Each part varies by prior treatments and combination regimens to assess safety and tolerability of these treatment approaches. Throughout the study, participants are monitored for adverse events, serious side effects, and dose-limiting toxicities up to about 2 years from the first dose. Blood samples are taken to measure drug levels up to around 112 days. Researchers also assess tumor response and disease control for up to 3 years. The study lasts several years with ongoing safety and effectiveness evaluations under medical supervision.
CONDITIONS
Brief Title
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
